[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100571660":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":33,"centralContacts":38,"locations":48,"responsibleParty":64,"collaborators":42,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":69,"sex":74,"minAge":75,"maxAge":42,"enrollmentInfo":76,"targetDuration":42,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":86,"overallStatus":50,"whyStopped":42,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"Kyoto University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Aspirin Continuation","EXPERIMENTAL","perioperative aspirin continuation",[13],"Drug: Aspirin",{"label":15,"type":16,"description":17,"interventionNames":18},"Interruption of Antiplatelet Therapy","ACTIVE_COMPARATOR","Interruption of aspirin 5-7 days before surgery",[19],"Drug: Aspirin interruption",[21,27],{"type":22,"name":23,"description":11,"armGroupLabels":24,"otherNames":25},"DRUG","Aspirin",[9],[26],"Aspirin (drug)",{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"Aspirin interruption","Aspirin interruption 5-7 days before surgery",[15],[32],"Aspirin interruption (drug)",[34],{"name":35,"affiliation":36,"role":37},"Hiroki Shiomi, MD, PhD","Kyoto University Hospital","PRINCIPAL_INVESTIGATOR",[39,44],{"name":35,"role":40,"phone":41,"phoneExt":42,"email":43},"CONTACT","+81-75-751-4255",null,"hishiomi@kuhp.kyoto-u.ac.jp",{"name":45,"role":40,"phone":46,"phoneExt":42,"email":47},"Erika Yamamoto, MD, PhD","+81-75-751-4254","erkymmt@kuhp.kyoto-u.ac.jp",[49],{"facility":36,"status":50,"city":51,"state":42,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"RECRUITING","Kyoto","606-8507","Japan","JP",{"type":56,"coordinates":57},"Point",[58,59],135.75385,35.02107,{"lat":59,"lon":58},[62],{"name":63,"role":40,"phone":41,"phoneExt":42,"email":43},"Hiroki Shiomi, MD",{"type":37,"investigatorFullName":65,"investigatorTitle":66,"investigatorAffiliation":5,"oldNameTitle":42,"oldOrganization":42},"Hiroki Shiomi","Hiroki Shiomi MD, PhD","100571660","phase-4-optimal-perioperative-antiplatelet-therapy-investigation-on-abdominal-surgery-after-coronary-stent-implantation-100571660",false,"NCT06723145","Optimal PERioperative Antiplatelet Therapy Investigation ON Abdominal Surgery After Coronary Stent Implantation","OPERATION","Inclusion Criteria:\n\n* Patients with a history of coronary stenting and scheduled for abdominal surgery\n* Patients on a single antiplatelet agent\n\nExclusion Criteria:\n\n* Patients on dual antiplatelet therapy (DAPT)\n* Patients on anticoagulation therapy\n* Patients with a history of stent thrombosis\n* Patients with CHADS2 score \\>= 5\n* Patients at extremely high risk of bleeding and unable to continue preoperative aspirin\n* Patients incapable of consent, including those under 20 years of age\n* Other patients for whom either discontinuation or continuation of antiplatelet agents is deemed inappropriate by the attending physician","ALL","20 Years",{"count":77,"type":78},1200,"ESTIMATED","INTERVENTIONAL",[81],"PHASE4","The purpose of this study is to evaluate the impact of perioperative aspirin continuation on clinical outcomes in patients with a history of coronary stent implantation who are scheduled for abdominal surgery.",[84,85],"Antiplatelet Agents","Perioperative Care",[87,88,89,90,91],"antiplatelet agents","perioperative care","coroanry artery disease","abdominal disease","noncardiac surgery","2025-02-09",{"date":94,"type":95},"2025-02-11","ACTUAL",{"date":97,"type":95},"2025-01-20",{"date":99,"type":78},"2027-03-31",{"name":5,"class":6},1]